Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SK Chemicals Co., Ltd.
SK3530 is a potent and selective phosphdiesterase type 5(PDE 5) inhibitor developed for the treatment of erectile dysfunction(ED). Since ED is common in men with hypertension, it is important to determine the efficacy and safety of SK3530 in men with ED taking antihypertensive medication.
Age
19–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Hypertension patient taking stable hypertensive medication for at least 4 weeks
Score below 25 from IIEF EF domain during 4 weeks of treatment run-in period
Failure rate above 50% from sexual attempt above 4 during 4 weeks of treatment run-in period
You may not be if
Lab abnormality
Uncontrolled diabetic mellitus
High or low blood pressure, orthostatic hypotension
Hyper- or hypo-thyroidism
Clareo Health | Phase III Study to Assess the Efficacy and Safety of SK3530 in Patients With Erectile Dysfunction and Hypertension
